Flamel Technologies

Venissieux, France Founded: 1990 • Age: 36 yrs Acquired By Recipharm
Formulation drug delivery company developing drugs for anaesthesia, CNS, respiratory diabetes disorders
Annual revenue - Latest available
Total funding - 1 rounds
Employees - Tracked headcount
Investors 2 Known backers
Products - Services tracked
Competitors - Brand Intelligence

About Flamel Technologies

Flamel Technologies is a company based in Venissieux (France) founded in 1990 by Gerard Soula was acquired by Recipharm in November 2014. Flamel Technologies has completed 1 acquisition, including FSC Pediatrics.

  • Headquarter Venissieux, France
  • Founders Gerard Soula
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    $15 M (USD), Debt – Venture

    Feb 07, 2013

  • Investors
    Recipharm

    & 1 more

  • Employee Count
    Not available
  • Investments & Acquisitions
  • Acquired by
    Recipharm

    (Nov 01, 2014)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Flamel Technologies

Investors in Flamel Technologies

Flamel Technologies has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Recipharm and Deerfield.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Healthcare ecosystem is supported through investment and innovation by Deerfield.
Locked Locked Locked
Pharmaceutical development and manufacturing services are offered contractually.
Locked Locked Locked
Premium access

Investor details for Flamel Technologies

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Flamel Technologies

Flamel Technologies has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include FSC Pediatrics.

Investments
Premium access

Investment portfolio details for Flamel Technologies

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Pediatric healthcare services are provided in Charlotte.
Locked Locked 2004 Locked
Premium access

Complete acquisition details for Flamel Technologies

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - Flamel Technologies

Premium access

Detailed financials for Flamel Technologies

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Flamel Technologies Comparisons

Flamel Technologies Primary company
Description
Formulation & drug delivery company developing drugs for ana...
Location
Venissieux, France
Founded Year
1990
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Flamel Technologies

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Flamel Technologies

Premium access

Detailed competitors of Flamel Technologies

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Flamel Technologies

Premium access

Complete news archive for Flamel Technologies

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Flamel Technologies

Flamel Technologies was founded in 1990 and raised its 1st funding round 23 years after it was founded.

Flamel Technologies is headquartered in Venissieux, France. It is registered at Venissieux, Auvergne-rhone-alpes, France.

Gerard Soula is the current CEO of Flamel Technologies. They have also founded this company.

Flamel Technologies is a specialty pharmaceutical company focussed in the formulation development and drug delivery to develop pharmaceutical products. It currently has 3 drugs in the USA for anesthesia namely Bloxiverz (neostigmine methylsulfate injection), Vazculep (phenylephrine hydrochloride injection) and Akovaz (ephedrine sulfate). Using its proprietary drug delivery platforms Micropump (oral sustained release microparticles platform), LiquiTime (a Micropump-derivative platform for liquid oral products) and Trigger Lock (a Micropump-derivative platform for abuse-resistant opioids), it is also developing its pipeline for CNS respiratory disorders which include sodium oxybate, an extended-release of liquid medicines such as ibuprofen and guaifenesin and also working on the delivery of exenatide utilizing the Medusa technology for diabetes. It acquired Eclat Pharmaceuticals FSC Pediatrics in March 2012 February 2016 respectively.

Flamel Technologies has made 1 acquisition, including FSC Pediatrics.

Flamel Technologies has 2 investors. Key investors include Recipharm, and Deerfield.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available